BIOMAT Database Logo BIOMAT Database Logo

Novel Gemini vitamin D(3) analogs have potent antitumor activity. 2008

Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Division of Hematology and Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA.

The active form of vitamin D(3), 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], modulates proliferation and induces differentiation of many cancer cells. A new class of analogs of vitamin D(3) has been synthesized, having two side-chains attached to carbon-20 (Gemini) and deuterium substituted on one side-chain. We have examined six of these analogs for their ability to inhibit growth of myeloid leukemia (HL-60), prostate (LNCaP, PC-3, DU145), lung (H520), colon (HT-29), and breast (MCF-7) cancer cell lines. Dose-response clonogenic studies showed that all six analogs had greater antiproliferative activities against cancer cells than 1,25(OH)(2)D(3). Although they had similar potency, the most active of these analogs was BXL-01-0120. BXL-01-0120 was 529-fold more potent than 1,25(OH)(2)D(3) in causing 50% clonal growth inhibition (ED(50)) of HL-60 cells. Pulse-exposure studies demonstrated that exposure to BXL-01-120 (10(-9)M, 48h) resulted in 85% clonal inhibition of HL-60 growth. BXL-01-0120 (10(-11)M, 4 days) induced the differentiation marker, CD11b. Also, morphologically differentiation was more prominent compared to 1,25(OH)(2)D(3). Annexin V assay showed that BXL-01-0120 (10(-10)M, 4 days) induced significantly (p<0.05) more apoptosis than 1,25(OH)(2)D(3). In summary, these analogs have a unique structure resulting in extremely potent inhibition of clonal proliferation of various types of cancer cells, especially HL-60 cells.

UI MeSH Term Description Entries
D002762 Cholecalciferol Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24. Vitamin D 3,(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol,Calciol,Cholecalciferols,Vitamin D3
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Gemini analogs of vitamin D.
January 2014, Current topics in medicinal chemistry,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Novel Gemini analogs of 1alpha,25-dihydroxyvitamin D(3) with enhanced transcriptional activity.
April 2004, Biochemical pharmacology,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs.
June 2010, Cancer letters,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
[Analogs of vitamin D and antiproliferative activity].
January 1993, Postepy biochemii,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Vitamin D(3) is more potent than vitamin D(2) in humans.
March 2011, The Journal of clinical endocrinology and metabolism,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
A novel class of aromatic vitamin D analogs.
May 2000, Current pharmaceutical design,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Novel vitamin d analogs for prostate cancer therapy.
January 2011, ISRN urology,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Vitamin D analogs.
February 2012, Rheumatic diseases clinics of North America,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
Vitamin D analogs.
June 2010, Endocrinology and metabolism clinics of North America,
Tsuyako Saito, and Ryoko Okamoto, and Talin Haritunians, and James O'Kelly, and Milan Uskokovic, and Hubert Maehr, and Stanislaw Marczak, and Pawel Jankowski, and Riem Badr, and H Phillip Koeffler
A vitamin D receptor selectively activated by gemini analogs reveals ligand dependent and independent effects.
February 2015, Cell reports,
Copied contents to your clipboard!